A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist).

Conference Paper

Full Text

Published version (via Digital Object Identifier)

Duke Authors

Melloni, Chiara

Cited Authors

Slovin, SF; Melloni, C; Mansor-Lefebvre, S; Neijber, A; Roe, M

Published Date

May 20, 2018

Published In

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

Volume / Issue

36 / 15_suppl

Start / End Page

TPS5101 - TPS5101

Published By

American Society of Clinical Oncology (ASCO)

Electronic International Standard Serial Number (EISSN)

1527-7755

International Standard Serial Number (ISSN)

0732-183X

Digital Object Identifier (DOI)

10.1200/jco.2018.36.15_suppl.tps5101